A. Japan Market Entry Strategy

​

Q1. What is the best way for a foreign biotech or MedTech company to enter Japan?

​​

Answer:

There is no single best route into Japan. The right model depends on the product, development stage, clinical evidence, regulatory pathway, reimbursement potential, resources and desired level of control. Options may include out-licensing, appointing a distributor, assigning a local designated marketing authorization holder (DMAH) or setting up a Japanese subsidiary. Many clinical-stage companies first assess partner-led models before investing in a full local organization.

​

Q2. When should a company start planning for Japan market entry?

​

Answer:

Ideally, companies should include Japan when forming global clinical development plans. Early assessment can clarify whether global data may support a Japan strategy, whether local evidence may be needed, which regulatory pathway is feasible and what commercial model is realistic. Waiting until after US or European approval can reduce flexibility, increase overall costs and delay regulatory preparation, partner discussions and launch planning.

​

Q3. Should Japan be part of a global launch strategy?

Answer:

Japan should be considered as part of a global launch strategy when the product addresses meaningful unmet needs and has a feasible regulatory, reimbursement and commercial pathway. This may be particularly relevant for specialty medicines, advanced therapies, medical devices and diagnostics in the fields of oncology, neurodegenerative disease, autoimmune/inflammatory and other rare diseases. The decision should reflect the available evidence, local execution requirements, investment needed and the company’s broader Asia Pacific objectives.

 

Q4. Can a company enter Japan after US or European approval?
 

Answer:

Yes. A company can enter Japan after US or European approval, but late planning may create avoidable delays. The existing evidence package must still be assessed against Japanese regulatory and reimbursement requirements. Additional analysis, documentation or local evidence may be needed. Earlier planning can align data strategy, partner selection and launch readiness, but an approved product can still present a viable Japan opportunity.

Q5. Is Japan worth pursuing for rare disease therapies?

Answer:

Japan is often a good market for rare disease therapeutics with clear differentiation and solid clinical evidence. Companies should assess patient identification, diagnosis rates, specialist networks, clinical requirements, reimbursement potential and local treatment patterns. Because rare disease opportunities are highly product-specific, the Japan case should be evaluated on its own evidence and commercial practicalities rather than assumed from global market potential.
 

Q6. What should companies evaluate before deciding to enter Japan?

Answer:

Before entering Japan, companies should evaluate unmet need, patient numbers, current standard-of-care, clinical evidence, regulatory requirements, reimbursement pricing potential, competition, partnering options and operational demands. The assessment should also test whether the required investment matches the company’s objectives and resources. Japan market entry is a combined clinical, regulatory and commercial decision, not simply an approval exercise.

Q7. What are the biggest risks of leaving Japan planning for later?

Answer:

Leaving Japan planning until later can limit clinical data options, delay regulatory work, weaken reimbursement preparation and reduce the range of potential partners. Key global decisions may already be fixed, making Japan harder or more expensive to include. Early evaluation does not require a commitment to enter the market. It preserves options and allows the company to make informed decisions as clinical and commercial evidence develops.

B. Regulatory, PMDA and Clinical Development

Q8. What is PMDA?

Answer:

PMDA is Japan’s Pharmaceuticals and Medical Devices Agency. It conducts scientific reviews of pharmaceuticals, medical devices, in vitro diagnostics and regenerative medicine products, and supports post-market safety activities. Japan’s Ministry of Health, Labor and Welfare is responsible for approval decisions and related administrative actions. PMDA also offers consultation services, with fees depending on the consultation type.

Q9. Can PMDA consider global clinical data?

Answer:

Yes. PMDA may consider global clinical data, but acceptance depends on the product, indication, study design, endpoints, patient population, ethnic sensitivity, safety profile and relevance to the Japanese treatment environment. Some programs may rely substantially on global evidence, while others may need Japan-specific data or additional analysis. Companies should assess this early in order to make the most efficient choices.

Q10. Do foreign companies always need Japanese clinical trials?

Answer:

No. Japanese clinical trials are not always required. The need depends on the product, regulatory pathway, existing evidence and relevance of the data to Japanese patients. Some programs may use global data, while others may require local participants, additional studies or bridging analysis. The evidence strategy should be assessed early because it can affect approval timing, development cost, reimbursement and the commercial case for Japan.

Q11. How long does PMDA approval take?

Answer:

PMDA review timelines vary by product, pathway and submission quality. A standard new drug and new device review have a 12-month target, but accelerated pathways, complex evidence packages or additional questions can change the timing. In 2025, for the first time ever, Japan’s average new drug review period was faster than both the FDA and the EMA.
 

Q12. What regulatory missteps steps do foreign companies often make?

Answer:

Common regulatory missteps include considering Japan much later than their US/global strategy, underestimating Japanese documentation and quality requirements and separating regulatory planning from reimbursement and commercial strategy. Another risk is choosing a local partner before the product pathway and responsibilities are clear. Companies should assess the full Japan route before fixing development plans or partner arrangements, keeping their options available for as long as possible.

Q13. How should foreign companies approach Japan regulatory strategy?

Answer:

A Japan regulatory strategy should begin with the product profile, indication, patient population, available evidence and intended commercial model. Companies should assess whether global data may support a filing, what additional local work could be required, which Japan-based authorization and quality roles are needed, and how the regulatory pathway affects reimbursement and launch timing. Early PMDA consultation may be appropriate for product-specific questions.

Q14. Why is local regulatory coordination important in Japan?

Answer:

Local regulatory coordination matters because Japan has specific requirements for documentation, communication, quality systems, local representation and post-market responsibilities. A capable Japan-based team can coordinate consultations, translations, document creation, support your strategizing and decision-making and handle the submission on your behalf. The Japan-based team will also need to support local KOL relations and reimbursement pricing strategy. The required support depends on the product, pathway and responsibilities assigned to each party.
 

​C. Market Access, Reimbursement and Commercial Readiness

Q15. How does reimbursement work in Japan?

 Answer:

Japan operates a national health insurance system, and many prescription drugs, medical devices and procedures require listing or coverage under the relevant reimbursement framework. The route depends on the product category, evidence, clinical value and comparator products. Regulatory approval does not itself guarantee favorable reimbursement pricing or adoption. Companies should assess this early and align regulatory evidence, pricing assumptions and launch preparation.

Q16. Why is reimbursement planning important before Japan launch?

Answer:

Reimbursement planning is important because approval alone does not define the commercial opportunity. Companies should understand the pricing of relevant comparators, evidence requirements for premium pricing and their likely pricing outcome before choosing a launch model. Early assessment may influence clinical evidence plans, partner discussions and investment decisions. It also helps determine whether the expected Japan opportunity is commercially realistic.

Q17. Can innovative products receive reimbursement in Japan?

Answer:

Yes. Innovative products receive reimbursement in Japan when they meet the relevant requirements and demonstrate value within the applicable framework. The outcome depends on the product category, comparators, strength of clinical evidence and the unmet need. Innovation alone does not guarantee coverage or favorable pricing. The clinical and economic value case should be supported by evidence relevant to Japanese patients and healthcare practice, and support from influential doctors is critical.

Q18. How are drug prices determined in Japan?

Answer:

New drug prices in Japan are calculated using a comparison method when an appropriate comparator drug exists, or a cost-based accounting method when one does not. Adjustments may reflect clinical usefulness, innovation, market characteristics and timeliness of Japan submission. The applicable method and resulting price depend on the product and evidence package. Companies should test realistic pricing assumptions early because they will affect partner interest, investment and launch strategy.

Q19. What market access questions should companies ask before entering Japan?

Answer:

Companies should ask whether the product addresses a clear need in Japan, which reimbursement route may apply, what evidence supports value, how it compares with current care, what pricing is realistic, and how patients will receive treatment. They should also identify the stakeholders who influence adoption. These questions should be assessed early before finalizing development, partnering or launch plans.

Q20. Why should regulatory and market access planning be connected?

Answer:

Regulatory and market access planning should be connected because the evidence supporting approval also affects reimbursement pricing and adoption. An approvable indication or study design may not create the strongest commercial position. Companies should assess whether endpoints, comparators, patient population, local evidence and timing support both regulatory review and post-approval access. This can prevent costly gaps between approval strategy and market needs.

Q21. What does commercial readiness mean in Japan?

Answer:

Commercial readiness means having the local structure, partner model, supply and distribution plan, compliance processes, medical affairs approach, price listing and stakeholder engagement needed for launch. It also requires clear responsibilities, budgets and decision-making. For foreign companies, readiness often depends on practical local execution rather than strategy alone. The required capabilities vary by product, launch ambition and market entry model.

D. Licensing, Distribution, DMAH and Subsidiary Models

Q22. Do foreign companies need a Japanese subsidiary to enter Japan?

Answer:

No. Many foreign healthcare companies enter Japan through out-licensing or distribution partnership rather than establishing a subsidiary. In order to retain overseas HQ ownership of their Japan marketing authorization, they can appoint a designated marketing authorization holder (DMAH) as their representative in Japan. This enables them to retain the option to transfer the DMAH to another party, including to their own subsidiary, in the future. The right approach depends on the product, regulatory requirements, resources and commercial objectives.

Q23. Should a company partner Japan rights or build its own subsidiary?

Answer:

The choice depends on the opportunity, resources and desired level of control. Licensing can be a lucrative source of revenue, and may enable optimization of the market opportunity. A subsidiary can provide closer control of strategy, assets and long-term growth, but requires capital, management and compliance infrastructure. Some companies use a phased or hybrid model, beginning by assigning a DMAH and building their own presence if the Japan business develops.

Q24 Can a foreign company sell directly in Japan?

Answer:

No. A foreign company cannot sell a regulated healthcare product directly into Japan without a DMAH acting on its behalf to manage regulatory, quality and safety responsibilities. 

Q25. What should companies look for in a Japan partner?

Answer:

Companies should look for relevant product experience, regulatory and market access knowledge, commercial capabilities, quality standards, operational capacity and strategic alignment. The partner should understand the intended patients and market-entry goals, communicate efficiently and provide clear accountability. Size alone is not enough. The best fit depends on the product, development stage, required responsibilities and the company’s preferred commercial model.

Q26. What are common mistakes when selecting a Japan partner?

Answer:

Common mistakes include choosing a partner mainly for size or name recognition, signing before the regulatory and reimbursement pathway is understood, and assuming sales coverage is sufficient. Companies may also leave responsibilities, decision rights, investment commitments and performance measures unclear. Partner selection should reflect the product’s needs, the capabilities required for execution and long-term strategic alignment, supported by practical due diligence.

E. HekaBio Capabilities, DMAH and Local Execution

Q27. How can HekaBio help foreign healthcare companies enter Japan?

Answer:

HekaBio helps overseas healthcare companies assess and execute practical Japan market entry plans. Depending on the asset and project, support may include opportunity assessment, regulatory coordination, market access planning, commercialization strategy, launch preparation, distribution and local commercial operations. HekaBio may become the licensee or distributor partner in some cases, and, in others, will support the selection a of a third3rd-party licensee or distributor partner. The scope is agreed case by case depending on product category, regulatory requirements, development stage and the company’s commercial objectives.

Q28. What regulatory and commercialization capabilities does HekaBio provide in Japan?

Answer:

HekaBio is fully licensed to obtain and hold regulatory approvals and commercialize assets across pharmaceuticals, medical devices, in vitro diagnostics and regenerative medicine products. HekaBio commercializes assets in its portfolio and offers its services to innovative companies that require a DMAH to launch in Japan.

Q29. What is a Designated Marketing Authorization Holder, or DMAH, in Japan?

Answer:

A Designated Marketing Authorization Holder, or DMAH, is a licensed Japan-based company appointed by a foreign entity to handle on its behalf the full responsibilities in Japan for its approved product, including regulatory file maintenance, quality and safety management and reporting.

Q30. Does HekaBio have DMAH experience in Japan?

Answer:

Yes, HekaBio has experience serving as a DMAH in Japan and will consider taking on additional DMAH programs for the right innovation and partner.

Q31. Why does DMAH experience matter for foreign companies?

Answer:

DMAH experience matters because the role carries practical Japan-based quality, safety and regulatory responsibilities. An experienced organization should be expected to coordinate more effectively with the foreign authorization holder, regulators and local service providers. However, DMAH experience alone is not enough. A company that has acted as DMAH may not have experience with a particular product category or regulatory pathway, so product-specific capability should always be assessed.

Q32. Does working with HekaBio mean a company does not need a Japanese subsidiary?

Answer:

Yes. HekaBio may become a foreign company’s licensee or distributor partner, help that company find another licensee or distributor partner or act as its DMAH, supporting a flexible structure. Neither of those scenarios requires the company to create a Japanese subsidiary. Also, the company is also not prevented from establishing or setting up a subsidiary. For example, HekaBio can serve as the company’s DMAH to handle statutory requirements while its Japanese, and the company can set up a Japan subsidiary initially to focus on sales and marketing, with the option of at first and taking over the DMAH role over time.

Q33. How is HekaBio different from a consultancy?

Answer:

HekaBio is an operating company whose primary role is in-licensing and growing commercial sales of its own portfolio. Utilizing its experience and contacts, HekaBio is also well positioned to offer hands-on support for licensing to 3rd parties in Japan. Additionally, HekaBio’s infrastructure and licenses enable it to offer a ready-made platform for commercialization as a DMAH. HekaBio is not a consultancy, but part of its activities overlap with what consultants do.

Q34. Can HekaBio support companies before product approval?

Answer:

Yes. HekaBio reviews the assets that come to it and hopes to provide helpful input to the product innovators, whether or not the product is in its own target area. HekaBio can support companies by assessing the Japan opportunity, regulatory pathway, evidence requirements, reimbursement opportunity and commercial model. Early work can help connect Japan requirements with global development plans and preserve strategic flexibility.

Q35. What HekaBio capabilities should be confirmed before publication?

Answer:

Before publication, HekaBio should confirm all statements about its licenses, authorizations, DMAH role, quality and safety responsibilities, product-category capabilities and experience with named products. The wording should be current, specific and consistent with the actual legal and operational scope. Regulatory, quality and legal review is particularly important where a statement could imply responsibility for approval, post-market obligations or regulated services.

F. Japan and Asia Pacific Expansion

Q36. Can Japan approval support expansion into the wider Asia Pacific region?

Answer:

Japan approval may support wider Asia Pacific expansion, but it does not replace approval in other markets. Its value depends on the country, product category and local regulatory framework. For some products, Japanese approval and market experience can strengthen credibility, generate useful evidence or support regional partner discussions. Companies should assess Japan as both a standalone market and a possible component of a broader regional strategy.

Q37. Why can Japan be strategically important for Asia Pacific healthcare commercialization?

Answer:

Japan can be strategically important because it is a major healthcare market with demanding standards for evidence, quality and compliance. A successful Japan program may build regional experience, strengthen credibility and support discussions with Asia Pacific partners. However, Japan is not a universal gateway to the region. Its strategic value depends on the product, target countries, evidence package, investment required and commercial objectives.

Q38. What types of companies are a good fit for HekaBio?

Answer:

HekaBio may be a good fit for overseas biotech, cell & gene therapy, medical device, diagnostic and other healthcare companies evaluating Japan or Asia Pacific. The strongest fit will be a company with an asset that has some level of patient data, clear strategic interest and a need for an experienced and flexible team in Japan.

Q39. What questions should a CEO or business development leader ask before approaching HekaBio?

Answer:

They should ask whether Japan is strategically important, what unmet need the product addresses, what evidence is available, which regulatory and reimbursement routes may apply, and what investment the company can support. They should also consider preferred entry models, timing and desired control. Clear internal objectives help HekaBio assess the opportunity and focus discussions on practical next steps.

Q40. How can companies start a Japan market entry discussion with HekaBio?

Answer:

Companies can begin by sharing a concise product overview, development stage, target indication, clinical evidence, regulatory status, Japan objectives and preferred commercial model, if known. Information on intellectual property, manufacturing, funding and target timing may also be relevant. HekaBio can then help identify the main Japan questions, assess whether further diligence is needed and discuss an appropriate path forward.

​